Literature DB >> 3740980

IgA-anti-yersinia antibodies in yersinia triggered reactive arthritis.

K Granfors, A Toivanen.   

Abstract

Patients who develop reactive arthritis after yersinia enteritis are characterised by high and persisting IgA-anti-yersinia antibodies. We have further analysed the humoral immune response to yersinia in this condition. Total concentrations of IgM, IgG, IgA, and secretory IgA in the serum and specific anti-yersinia antibodies belonging to IgA1, IgA2, or secretory IgA were compared in patients with or without reactive arthritis. In the former group the serum concentration of secretory IgA and of yersinia specific antibodies in all categories studied was raised compared with the level in patients without joint symptoms; the difference was most significant for the IgA-anti-yersinia antibodies with secretory piece or with J chain. The findings suggest that the strong antibody response in the patients developing reactive arthritis is due to a chronic stimulation of the intestinal lymphoid tissue.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3740980      PMCID: PMC1001937          DOI: 10.1136/ard.45.7.561

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  32 in total

1.  HL-A 27 in reactive arthritis. A study of Yersinia arthritis and Reiter's disease.

Authors:  K Aho; P Ahvonen; A Lassus; K Sievers; A Tiilikainen
Journal:  Arthritis Rheum       Date:  1974 Sep-Oct

2.  Yersiniosis as an internal disease.

Authors:  R Leino; J L Kalliomäki
Journal:  Ann Intern Med       Date:  1974-10       Impact factor: 25.391

3.  Hospital outbreak of Yersinia enterocolitica infection.

Authors:  P Toivanen; A Toivanen; L Olkkonen; S Aantaa
Journal:  Lancet       Date:  1973-04-14       Impact factor: 79.321

4.  Enteric infection with Yersinia enterocolitica. Large pyroninophilic cell reaction in mesenteric lymph nodes associated with early production of specific antibodies.

Authors:  J Ahlqvist; P Ahvonen; J A Räsänen; G R Wallgren
Journal:  Acta Pathol Microbiol Scand A       Date:  1971

5.  Bactericidal activity of meningococcal antisera. Blocking by IgA of lytic antibody in human convalescent sera.

Authors:  J M Griffiss
Journal:  J Immunol       Date:  1975-06       Impact factor: 5.422

6.  Influence of tubercle aggregate size on severity of adjuvant arthritis in the rat.

Authors:  S P Liyanage; H L Currey; B Vernon-Roberts
Journal:  Ann Rheum Dis       Date:  1975-02       Impact factor: 19.103

7.  Follow-up studies of joint complications in yersiniosis.

Authors:  J L Kalliomäki; R Leino
Journal:  Acta Med Scand       Date:  1979

8.  Measurement of immunoglobulin M (IgM), IgG, and IgA antibodies against Yersinia enterocolitica by enzyme-linked immunosorbent assay: persistence of serum antibodies during disease.

Authors:  K Granfors
Journal:  J Clin Microbiol       Date:  1979-03       Impact factor: 5.948

9.  Distribution of IgA 1 and IgA 2 plasma cells in various normal human tissues and in the jejunum of plasma IgA-deficient patients.

Authors:  C André; F André; C Fargier
Journal:  Clin Exp Immunol       Date:  1978-08       Impact factor: 4.330

10.  Subclass distribution and molecular form of immunoglobulin A hemagglutinin antibodies in sera and nasal secretions after experimental secondary infection with influenza A virus in humans.

Authors:  T A Brown; B R Murphy; J Radl; J J Haaijman; J Mestecky
Journal:  J Clin Microbiol       Date:  1985-08       Impact factor: 5.948

View more
  27 in total

1.  CD14 triggers autoimmune Type 1 diabetes in the NOD mouse.

Authors:  N Klöting; I Klöting; R S Jack
Journal:  Diabetologia       Date:  2003-11-12       Impact factor: 10.122

Review 2.  Small intestinal mucosal protection mechanisms and their importance in rheumatology.

Authors:  S O'Mahony; A Ferguson
Journal:  Ann Rheum Dis       Date:  1991-05       Impact factor: 19.103

3.  Neutrophil functions and IL-8 in psoriatic arthritis and in cutaneous psoriasis.

Authors:  D Biasi; A Carletto; P Caramaschi; P Bellavite; T Maleknia; C Scambi; N Favalli; L M Bambara
Journal:  Inflammation       Date:  1998-10       Impact factor: 4.092

Review 4.  HLA-B27 and bacteria.

Authors:  J Uksila; P Toivanen
Journal:  Clin Rheumatol       Date:  1996-01       Impact factor: 2.980

5.  Serum secretory immunoglobulins in ankylosing spondylitis.

Authors:  D Wendling; J M Didier; E Seilles
Journal:  Clin Rheumatol       Date:  1996-11       Impact factor: 2.980

6.  Synovial T lymphocyte recognition of organisms that trigger reactive arthritis.

Authors:  J S Gaston; P F Life; K Granfors; R Merilahti-Palo; L Bailey; S Consalvey; A Toivanen; P A Bacon
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

7.  Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis.

Authors:  T Yli-Kerttula; R Luukkainen; U Yli-Kerttula; T Möttönen; M Hakola; M Korpela; M Sanila; J Parviainen; J Uksila; R Vainionpää; A Toivanen
Journal:  Ann Rheum Dis       Date:  2000-07       Impact factor: 19.103

8.  Polymorphonuclear leucocyte motility in men with ankylosing spondylitis.

Authors:  C T Pease; M Fennell; D A Brewerton
Journal:  Ann Rheum Dis       Date:  1989-01       Impact factor: 19.103

Review 9.  Immunological and bacteriological aspects of reactive arthritis.

Authors:  A Toivanen; K Granfors; R Lahesmaa-Rantala; P Toivanen
Journal:  Rheumatol Int       Date:  1989       Impact factor: 2.631

10.  Humoral immune response to individual Yersinia enterocolitica antigens in patients with and without reactive arthritis.

Authors:  A Grönberg; A Frydén; E Kihlström
Journal:  Clin Exp Immunol       Date:  1989-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.